{
    "id": 2967,
    "fullName": "HRAS G12V",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "HRAS G12V is hotspot mutation that lies within a GTP nucleotide binding region of the Hras protein (UniProt.org). G12V results in decreased Hras GTPase activity, loss of response to GTPase-activating proteins, leading to activation of downstream signaling pathways, and transformation of cultured cells (PMID: 24224811, PMID: 21850009, PMID: 6330729).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1783,
                    "pubMedId": 21850009,
                    "title": "HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21850009"
                },
                {
                    "id": 1784,
                    "pubMedId": 6330729,
                    "title": "Analysis of the transforming potential of the human H-ras gene by random mutagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/6330729"
                },
                {
                    "id": 12348,
                    "pubMedId": 24224811,
                    "title": "Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24224811"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3265,
        "geneSymbol": "HRAS",
        "terms": [
            "HRAS",
            "C-BAS/HAS",
            "C-H-RAS",
            "C-HA-RAS1",
            "CTLO",
            "H-RASIDX",
            "HAMSV",
            "HRAS1",
            "p21ras",
            "RASH1"
        ]
    },
    "variant": "G12V",
    "createDate": "01/24/2015",
    "updateDate": "10/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 132122,
        "transcript": "NM_001130442",
        "gDna": "chr11:g.534288C>A",
        "cDna": "c.35G>T",
        "protein": "p.G12V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1692,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1793,
                    "pubMedId": 22797062,
                    "title": "Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22797062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8554,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rigosertib (ON 01910.Na) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6686,
                    "pubMedId": 27104980,
                    "title": "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27104980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5211,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 915,
                "therapyName": "SF1126",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4921,
                    "pubMedId": 25425962,
                    "title": "Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)\u2009V-Ha-Ras transgenic mouse glioma model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25425962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR9011 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 6651,
                "therapyName": "SR9011",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10714,
                    "pubMedId": 29320480,
                    "title": "Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6193,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 4089,
                "therapyName": "Pz-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5385,
                    "pubMedId": 26126987,
                    "title": "Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26126987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5784,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12785,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR9009 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 6650,
                "therapyName": "SR9009",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10714,
                    "pubMedId": 29320480,
                    "title": "Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9476,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9465,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 4901,
                "therapyName": "Everolimus + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1693,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1793,
                    "pubMedId": 22797062,
                    "title": "Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22797062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9480,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 5022,
                "therapyName": "Binimetinib + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19450,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WM-8014 inhibited proliferation of a transformed mouse cell line expressing HRAS G12V in culture, and inhibited proliferation and induced senescence in a transgenic zebrafish model (PMID: 30069049).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 9048,
                "therapyName": "WM-8014",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17087,
                    "pubMedId": 30069049,
                    "title": "Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30069049"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9464,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 5022,
                "therapyName": "Binimetinib + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2576,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13021,
                "profileName": "FGFR3 dec exp FGFR3 wild-type HRAS G12V"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2575,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13021,
                "profileName": "FGFR3 dec exp FGFR3 wild-type HRAS G12V"
            },
            "therapy": {
                "id": 2955,
                "therapyName": "AZ8010",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3278,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13021,
                "profileName": "FGFR3 dec exp FGFR3 wild-type HRAS G12V"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8134,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V were resistant to Odomzo (sonidegib) in culture and in cell line xenograft models (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8126,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8132,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V were resistant to Erivedge (vismodegib) in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8127,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8131,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V were resistant to LEQ506 in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 2416,
                "therapyName": "LEQ506",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8124,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BKM120 inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing HRAS G12V in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26164,
                "profileName": "HRAS G12V PTCH1 inact mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2794,
            "profileName": "HRAS G12V",
            "profileTreatmentApproaches": [
                {
                    "id": 203,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 1175,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 206,
                    "name": "PIK3CD inhibitor",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 210,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 208,
                    "name": "MEK2 Inhibitor",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 204,
                    "name": "PIK3CA inhibitor",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 205,
                    "name": "PIK3CB inhibitor",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 207,
                    "name": "PIK3CG inhibitor",
                    "profileName": "HRAS G12V"
                },
                {
                    "id": 209,
                    "name": "MEK1 Inhibitor",
                    "profileName": "HRAS G12V"
                }
            ]
        },
        {
            "id": 13021,
            "profileName": "FGFR3 dec exp FGFR3 wild-type HRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26164,
            "profileName": "HRAS G12V PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 132122,
            "transcript": "NM_001130442",
            "gDna": "chr11:g.534288C>A",
            "cDna": "c.35G>T",
            "protein": "p.G12V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 132123,
            "transcript": "NM_176795",
            "gDna": "chr11:g.534288C>A",
            "cDna": "c.35G>T",
            "protein": "p.G12V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 132121,
            "transcript": "NM_005343",
            "gDna": "chr11:g.534288C>A",
            "cDna": "c.35G>T",
            "protein": "p.G12V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}